PubRank

Steven M Albelda

Author PubWeight™ 148.39‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002 8.55
2 Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 2009 8.21
3 Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A 2009 5.36
4 Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005 5.16
5 Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 2007 4.65
6 The junctional adhesion molecule JAM-C regulates polarized transendothelial migration of neutrophils in vivo. Nat Immunol 2011 3.04
7 Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res 2010 2.64
8 A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. J Cell Sci 2003 2.34
9 Tumor-associated neutrophils: friend or foe? Carcinogenesis 2012 2.15
10 Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 2005 1.86
11 A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res 2007 1.78
12 PECAM-directed delivery of catalase to endothelium protects against pulmonary vascular oxidative stress. Am J Physiol Lung Cell Mol Physiol 2003 1.74
13 Alterations in cell cycle genes in early stage lung adenocarcinoma identified by expression profiling. Cancer Biol Ther 2003 1.65
14 ANGPT2 genetic variant is associated with trauma-associated acute lung injury and altered plasma angiopoietin-2 isoform ratio. Am J Respir Crit Care Med 2011 1.62
15 Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res 2011 1.53
16 Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells. Am J Respir Cell Mol Biol 2010 1.51
17 Variation in the myosin light chain kinase gene is associated with development of acute lung injury after major trauma. Crit Care Med 2008 1.50
18 Gene therapy for mesothelioma and lung cancer. Am J Respir Cell Mol Biol 2010 1.49
19 CCL2 blockade augments cancer immunotherapy. Cancer Res 2009 1.48
20 A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res 2007 1.47
21 Immunotargeting of catalase to the pulmonary endothelium alleviates oxidative stress and reduces acute lung transplantation injury. Nat Biotechnol 2003 1.46
22 Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma. Respirology 2005 1.45
23 Gene expression profiling of the early pulmonary response to hyperoxia in mice. Am J Respir Cell Mol Biol 2003 1.41
24 Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils. PLoS One 2012 1.40
25 Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Cancer Res 2005 1.40
26 Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clin Cancer Res 2006 1.40
27 Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Res Treat 2012 1.39
28 Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy. Cancer Res 2008 1.38
29 PECAM-1 functions as a specific and potent inhibitor of mitochondrial-dependent apoptosis. Blood 2003 1.33
30 Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J Clin Invest 2014 1.33
31 Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin Cancer Res 2008 1.32
32 Urinary volatile compounds as biomarkers for lung cancer: a proof of principle study using odor signatures in mouse models of lung cancer. PLoS One 2010 1.31
33 Size-dependent intracellular immunotargeting of therapeutic cargoes into endothelial cells. Blood 2002 1.30
34 ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface. Blood 2003 1.28
35 Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Res 2009 1.27
36 Intrapulmonary IFN-beta gene therapy using an adenoviral vector is highly effective in a murine orthotopic model of bronchogenic adenocarcinoma of the lung. Cancer Res 2005 1.26
37 Resection of non-small cell lung cancers reverses tumor-induced gene expression changes in the peripheral immune system. Clin Cancer Res 2011 1.24
38 Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms. Mol Ther 2010 1.23
39 Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin Cancer Res 2005 1.19
40 Endothelial targeting of semi-permeable polymer nanocarriers for enzyme therapies. Biomaterials 2007 1.17
41 Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases. Cancer Res 2013 1.16
42 A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Mol Ther 2010 1.15
43 Gemcitabine has significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects. Cancer Biol Ther 2007 1.15
44 The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther 2009 1.15
45 Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature. Blood 2005 1.15
46 T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res 2013 1.14
47 Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature. Blood 2007 1.14
48 Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy. Hum Gene Ther 2010 1.14
49 Targeted detoxification of selected reactive oxygen species in the vascular endothelium. J Pharmacol Exp Ther 2009 1.11
50 A 10-gene classifier for distinguishing head and neck squamous cell carcinoma and lung squamous cell carcinoma. Clin Cancer Res 2007 1.10
51 Gene expression profiling of malignant mesothelioma. Clin Cancer Res 2003 1.10
52 Platelet-endothelial cell adhesion molecule-1-directed endothelial targeting of superoxide dismutase alleviates oxidative stress caused by either extracellular or intracellular superoxide. J Pharmacol Exp Ther 2007 1.10
53 Dissociation between alveolar transmigration of neutrophils and lung injury in hyperoxia. Am J Physiol Lung Cell Mol Physiol 2006 1.08
54 Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res 2013 1.07
55 A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma. Am J Respir Crit Care Med 2011 1.07
56 B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models. J Immunother 2008 1.07
57 The vascular disrupting agent, DMXAA, directly activates dendritic cells through a MyD88-independent mechanism and generates antitumor cytotoxic T lymphocytes. Cancer Res 2007 1.06
58 PECAM-1-dependent neutrophil transmigration is independent of monolayer PECAM-1 signaling or localization. Blood 2002 1.06
59 Differential intra-endothelial delivery of polymer nanocarriers targeted to distinct PECAM-1 epitopes. J Control Release 2008 1.06
60 Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity. Mol Ther 2011 1.06
61 Immuno-gene therapy with interferon-beta before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma. J Thorac Cardiovasc Surg 2004 1.05
62 Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy. Cancer Res 2003 1.04
63 Activation of the nucleotide oligomerization domain signaling pathway by the non-bacterially derived xanthone drug 5'6-dimethylxanthenone-4-acetic acid (Vadimezan). J Biol Chem 2010 1.04
64 Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM). Sci Transl Med 2012 1.03
65 Anchoring fusion thrombomodulin to the endothelial lumen protects against injury-induced lung thrombosis and inflammation. Am J Respir Crit Care Med 2009 1.03
66 Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. Am J Respir Crit Care Med 2009 1.02
67 Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity. Clin Cancer Res 2004 1.02
68 Inhibition of p300 impairs Foxp3⁺ T regulatory cell function and promotes antitumor immunity. Nat Med 2013 1.02
69 Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biol Ther 2005 1.00
70 Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing. Cancer Gene Ther 2003 1.00
71 Platelet-endothelial cell adhesion molecule-1-directed immunotargeting to cardiopulmonary vasculature. J Pharmacol Exp Ther 2002 1.00
72 Progression of human bronchioloalveolar carcinoma to invasive adenocarcinoma is modeled in a transgenic mouse model of K-ras-induced lung cancer by loss of the TGF-β type II receptor. Cancer Res 2011 0.97
73 Peripheral immune cell gene expression predicts survival of patients with non-small cell lung cancer. PLoS One 2012 0.96
74 Vascular endothelial-targeted therapy combined with cytotoxic chemotherapy induces inflammatory intratumoral infiltrates and inhibits tumor relapses after surgery. Neoplasia 2012 0.96
75 Microarray data simulator for improved selection of differentially expressed genes. Cancer Biol Ther 2003 0.94
76 Cytoreduction surgery reduces systemic myeloid suppressor cell populations and restores intratumoral immunotherapy effectiveness. J Hematol Oncol 2012 0.94
77 Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy. Eur J Cancer 2010 0.94
78 Neutrophils recruit regulatory T-cells into tumors via secretion of CCL17--a new mechanism of impaired antitumor immunity. Int J Cancer 2014 0.94
79 Distinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cells. PLoS One 2008 0.94
80 Interferon beta adenoviral gene therapy in a patient with ovarian cancer. Nat Clin Pract Oncol 2006 0.92
81 Vascular immunotargeting of glucose oxidase to the endothelial antigens induces distinct forms of oxidant acute lung injury: targeting to thrombomodulin, but not to PECAM-1, causes pulmonary thrombosis and neutrophil transmigration. Am J Pathol 2002 0.92
82 Advanced glycation end products on stored red blood cells increase endothelial reactive oxygen species generation through interaction with receptor for advanced glycation end products. Transfusion 2010 0.92
83 Activation of mitogen-activated protein kinases by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) plays an important role in macrophage stimulation. Biochem Pharmacol 2011 0.91
84 Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients. Oncoimmunology 2013 0.91
85 Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors. J Clin Invest 2013 0.90
86 Lower serum endocan levels are associated with the development of acute lung injury after major trauma. J Crit Care 2011 0.89
87 Role of lateral cell-cell border location and extracellular/transmembrane domains in PECAM/CD31 mechanosensation. Biochem Biophys Res Commun 2004 0.89
88 Cytokine gene therapy for malignant pleural mesothelioma. J Thorac Oncol 2007 0.89
89 Treatment of lung cancer using clinically relevant oral doses of the cyclooxygenase-2 inhibitor rofecoxib: potential value as adjuvant therapy after surgery. Ann Surg 2005 0.88
90 Modulation of endothelial targeting by size of antibody-antioxidant enzyme conjugates. J Control Release 2010 0.88
91 Platelet endothelial cell adhesion molecule-1 in neutrophil emigration during acute bacterial pneumonia in mice and rats. Am J Respir Crit Care Med 2003 0.87
92 Factors modulating the delivery and effect of enzymatic cargo conjugated with antibodies targeted to the pulmonary endothelium. J Control Release 2007 0.87
93 Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation. Hum Gene Ther 2002 0.86
94 Targeted endothelial delivery of nanosized catalase immunoconjugates protects lung grafts donated after cardiac death. Transplantation 2011 0.86
95 PECAM-1 (CD31) regulates a hydrogen peroxide-activated nonselective cation channel in endothelial cells. J Cell Biol 2002 0.86
96 Pharmacologic activation of the innate immune system to prevent respiratory viral infections. Am J Respir Cell Mol Biol 2010 0.85
97 Detection of SV40 DNA sequences in malignant mesothelioma specimens from the United States, but not from Turkey. J Cell Biochem 2002 0.84
98 Gene therapy for lung neoplasms. Clin Chest Med 2011 0.84
99 The Optical Biopsy: A Novel Technique for Rapid Intraoperative Diagnosis of Primary Pulmonary Adenocarcinomas. Ann Surg 2015 0.83
100 Differentially expressed apoptotic genes in early stage lung adenocarcinoma predicted by expression profiling. Cancer Biol Ther 2003 0.81
101 The receptor for advanced glycation end products mediates lung endothelial activation by RBCs. Am J Physiol Lung Cell Mol Physiol 2012 0.81
102 Blockade of TNF-alpha decreases both inflammation and efficacy of intrapulmonary Ad.IFNbeta immunotherapy in an orthotopic model of bronchogenic lung cancer. Mol Ther 2006 0.80
103 Flaxseed lignans enriched in secoisolariciresinol diglucoside prevent acute asbestos-induced peritoneal inflammation in mice. Carcinogenesis 2015 0.79
104 Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma. J Thorac Oncol 2013 0.78
105 TNFerade to the rescue? Guidelines for evaluating phase I cancer gene transfer trials. J Clin Oncol 2004 0.78
106 The timing of TGF-β inhibition affects the generation of antigen-specific CD8+ T cells. BMC Immunol 2013 0.78
107 Gene therapy for mesothelioma. Curr Treat Options Oncol 2011 0.76
108 Novel variants in the PRDX6 Gene and the risk of Acute Lung Injury following major trauma. BMC Med Genet 2011 0.76